Drug Profile

GC 376

Alternative Names: GC-376

Latest Information Update: 28 Nov 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kansas State University
Developer Anivive Lifesciences
Class Amines; Antivirals; Pyrrolidinones; Small molecules; Sulfonic acids
Mechanism of Action Coronavirus 3C-like proteinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported COVID 2019 infections

Most Recent Events

28 Nov 2022 No recent reports of development identified for preclinical development in COVID-2019-infections in USA
23 Jul 2021 Pharmacodynamics data from a preclinical trial in COVID-2019 infections released by Anivive Lifesciences
01 Jul 2020 Anivive Lifesciences plans a phase I clinical trial for COVID-2019 infections by the end of 2020

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com